- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03794492
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome
July 6, 2021 updated by: Chong Kun Dang Pharmaceutical
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome: Open-label, Multi-center, Single Arm, Phase 4 Trial (DoSAKOM)
Efficacy and Safety of My-Rept® (Mycophenolate Mofetil 500mg/Tab.
or 250mg/Cap.) in Combination with Tacrolimus, Methylprednisolone, Simulect in Kidney Transplant Patients
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
This study is a multi-center, non-comparative and phase IV clinical trial that evaluates incidence of Donor-Specific Antibody for 36 months after kidney transplantation when administered with Tacrolimus, Mycophenolate mofetil, and corticosteroid
Study Type
Interventional
Enrollment (Actual)
169
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Suwan, Korea, Republic of
- Ajou University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Over 19 years old(male or female)
- Patients who are planning to receive a kidney from a deceased or a living unrelated/related donor
- Agreement with written informed consent
Exclusion Criteria:
- Donor's HLA antigen matches recipient or the Degree of Mis-Match is 0
- Patients with high sensitization who need desensitization therapy
- Multi organ recipients or previous transplant with any organs
- Diagnosed with cancer within five years
- Patient who receive kidney from ABO incompatibility donor or Lymphocyte cross-match positive donor
- Patients who have positive HIV, HBsAg or Anti-HCV test result
At screening
- Under treatment for active liver disease, or Over 3times upper than normal range of liver function test (T-bilirubin, AST, ALT)
- WBC<2,500/mm3, PLT <50,000/mm3, ANC<1,500/mm3
- Pregnant or lactating women
- In investigator's judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mycophenolate mofetil
One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
|
- Orally, up to 1g BID(total 2g daily)
Other Names:
- Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml
- Methyprednisolone 500mg / Prednisolone 5mg
- IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DSA(Donor-specific Anti-HLA Antibody)
Time Frame: 36 months
|
Incidence of DSA(Donor-specific Anti-HLA Antibody) up to 36months after Kidney transplantation
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of composite efficacy failure
Time Frame: 12, 24, 36months
|
The frequency and percentage of composite efficacy failure (Treated-BPAMR & ACR, graft loss, death and follow-up loss)
|
12, 24, 36months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Chang-Kwan Oh, Ph.D, Ajou University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2018
Primary Completion (Anticipated)
August 11, 2022
Study Completion (Anticipated)
December 29, 2022
Study Registration Dates
First Submitted
January 3, 2019
First Submitted That Met QC Criteria
January 3, 2019
First Posted (Actual)
January 7, 2019
Study Record Updates
Last Update Posted (Actual)
July 9, 2021
Last Update Submitted That Met QC Criteria
July 6, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Prednisolone
- Methylprednisolone
- Tacrolimus
- Mycophenolic Acid
- Basiliximab
Other Study ID Numbers
- 223KT17017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplant
-
University of MinnesotaWithdrawnKidney Transplant Rejection | Kidney Transplant; Complications | Kidney Transplant FailureUnited States
-
Ajay IsraniNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingKidney Transplant Rejection | Kidney TransplantUnited States
-
Ohio State UniversityActive, not recruitingKidney Transplant; Complications | Kidney TransplantUnited States
-
Providence Health & ServicesWashington State University; Paul I Terasaki Foundation LaboratoryUnknownKidney Transplant | Kidney/Pancreas TransplantUnited States
-
Hospital de Clinicas de Porto AlegreActive, not recruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant Failure | Kidney Transplant Failure and RejectionBrazil
-
University of MinnesotaCompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant DysfunctionUnited States
-
University of LiegeRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsBelgium
-
Liverpool University Hospitals NHS Foundation TrustKidney Research United KingdomNot yet recruitingFrailty | Kidney Transplant Rejection | Renal Transplant | Diagnosis | Kidney Transplant; Complications | Kidney Transplant | Renal Transplant Failure | Transplant DysfunctionUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; Clinical Trials in Organ TransplantationCompletedKidney Transplant Recipients | Living-Donor Kidney TransplantUnited States
-
Singapore General HospitalRecruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant; ComplicationsSingapore
Clinical Trials on Mycophenolate mofetil 500mg Tab. or 250mg Cap.
-
Chong Kun Dang PharmaceuticalCompletedKidney TransplantationKorea, Republic of
-
Fred Hutchinson Cancer CenterUniversity of WashingtonCompleted
-
Chong Kun Dang PharmaceuticalNot yet recruitingKidney TransplantationKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknownLiver TransplantKorea, Republic of
-
Chong Kun Dang PharmaceuticalRecruitingKidney TransplantationKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.CompletedHelicobacter InfectionsKorea, Republic of
-
Yuhan CorporationCompletedChronic PeriodontitisKorea, Republic of
-
Onconic Therapeutics Inc.CompletedHelicobacter Pylori Associated Gastrointestinal DiseaseKorea, Republic of
-
Chong Kun Dang PharmaceuticalNot yet recruiting
-
University College, LondonVersus ArthritisActive, not recruitingSystemic Sclerosis | Limited Cutaneous Systemic SclerosisUnited Kingdom